Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861348 | 0.81 | MAPT (0.39) | CYP1A2 | |
| SCHEMBL7860232 | 0.80 | CYSLTR1 (0.45) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL855577 | 0.76 | PDE1B (0.45) | PDE10ACYP1A2 | |
| SCHEMBL857004 | 0.71 | PDE1B (0.40) | — | |
| SCHEMBL7454262 | 0.69 | PDE10A (0.57) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL10465701 | 0.68 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL7459197 | 0.68 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10547704 | 0.68 | PDE10A (0.64) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL10547475 | 0.68 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10533356 | 0.68 | PDE10A (0.52) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | CYSLTR1 3002/4885CYSLTR2 2680/4885PDE10A 758/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | CYSLTR1 3075/4885CYSLTR2 2930/4885PDE10A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.